Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P42574 (
caspase-3
)
45,978
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Oral carcinomas
are known to have a greater apoptotic index than normal oral epithelium, evident as shrinking cells with condensed chromatin. In this study, these morphologically apoptotic cells stained positively for cleaved (active)
caspase-3
. In normal oral epithelium, cleaved
caspase-3
positive-cells were only rarely detected. The terminally differentiated surface epithelial layers did not express cleaved
caspase-3
. The
caspase-3
pro-enzyme showed a gradient of expression in normal oral epithelium, decreasing with differentiation. No expression was detectable in surface epithelial layers. Lack of expression of the major 'executioner'
caspase-3
may, at least in part, explain differences in morphology between terminally differentiated and apoptotic cells. In cancers of different tissue origins,
caspase-3
pro-enzyme expression can be either increased or decreased compared with normal tissue counterparts. To determine how
caspase-3
expression alters during oral carcinogenesis,
caspase-3
expression was compared in 39 samples of normal oral epithelium and 54 oral squamous cell carcinomas. Squamous cell carcinomas had more intense
caspase-3
staining than normal epithelium (p < 0.001). Moreover, within the oral squamous cell carcinoma series, there was significantly more intense nuclear and cytoplasmic staining with increasing STNMP stage (p = 0.017 and 0.03, respectively). This was a reflection of significant associations with site (S), palpable lymph nodes (N), and differentiation (P). Both
caspase-3
staining intensity and the percentage of cells positive for
caspase-3
were inversely associated with differentiation. Studies of the mechanisms by which high levels of
caspase-3
expression are tolerated in oral carcinoma cells may identify targets that can be used to harness
caspase-3
overexpression for therapeutic benefit.
...
PMID:Caspase-3 expression is reduced, in the absence of cleavage, in terminally differentiated normal oral epithelium but is increased in oral squamous cell carcinomas and correlates with tumour stage. 1537 56